A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

July 31, 2027

Conditions
Esophageal CancerNon Small Cell Lung CancerCervical Cancer
Interventions
RADIATION

Pulsed low dose rate radiotherapy (PLDR)

Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.

DRUG

Alpaloritovorelli antibodies

PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.

All Listed Sponsors
collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Anhui Provincial Hospital

OTHER_GOV